After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
ABUS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Arbutus Biopharma Corp is $715.48M. A total of 0.65 million shares were traded on the day, compared to an average of 1.12M shares.
In the most recent transaction, MANCHESTER KEITH S sold 8,846 shares of ABUS for 3.69 per share on Aug 14 ’24. After the transaction, the Director now owns 46,069 company shares. In a previous transaction on Feb 02 ’24, Sims Karen sold 4,358 shares at 2.31 per share. ABUS shares that Chief Medical Officer owns now total 125,542.
Among the insiders who sold shares, HASTINGS DAVID C disposed of 9,593 shares on Feb 02 ’24 at a per-share price of $2.31. This resulted in the Chief Financial Officer holding 181,907 shares of ABUS after the transaction. In another insider transaction, Sofia Michael J. sold 9,982 shares at $2.31 per share on Feb 02 ’24. Company shares held by the Chief Scientific Officer now total 1,485,121.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ABUS has a high of $4.72 and a low of $1.69.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.65, while its Total Shareholder’s Equity was $169.44M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.
